- Home
- PERF vs VYGR Comparison
PERF vs VYGR Comparison
Compare PERF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- VYGR
- Stock Information
- Founded
- PERF 2015
- VYGR 2013
- Country
- PERF Taiwan
- VYGR United States
- Employees
- PERF N/A
- VYGR N/A
- Industry
- PERF Computer Software: Prepackaged Software
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- PERF Technology
- VYGR Health Care
- Exchange
- PERF Nasdaq
- VYGR Nasdaq
- Market Cap
- PERF 230.2M
- VYGR 222.9M
- IPO Year
- PERF N/A
- VYGR 2015
- Fundamental
- Price
- PERF $1.79
- VYGR $4.07
- Analyst Decision
- PERF Buy
- VYGR Strong Buy
- Analyst Count
- PERF 1
- VYGR 10
- Target Price
- PERF $5.00
- VYGR $15.75
- AVG Volume (30 Days)
- PERF 192.8K
- VYGR 352.2K
- Earning Date
- PERF 04-23-2025
- VYGR 03-11-2025
- Dividend Yield
- PERF N/A
- VYGR N/A
- EPS Growth
- PERF 8.96
- VYGR N/A
- EPS
- PERF 0.05
- VYGR N/A
- Revenue
- PERF $60,202,000.00
- VYGR $80,001,000.00
- Revenue This Year
- PERF $17.47
- VYGR N/A
- Revenue Next Year
- PERF $13.15
- VYGR $23.46
- P/E Ratio
- PERF $36.00
- VYGR N/A
- Revenue Growth
- PERF 12.52
- VYGR N/A
- 52 Week Low
- PERF $1.70
- VYGR $3.56
- 52 Week High
- PERF $3.44
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- PERF 40.11
- VYGR 38.31
- Support Level
- PERF $1.75
- VYGR $3.56
- Resistance Level
- PERF $1.97
- VYGR $4.32
- Average True Range (ATR)
- PERF 0.17
- VYGR 0.22
- MACD
- PERF -0.00
- VYGR 0.05
- Stochastic Oscillator
- PERF 8.94
- VYGR 66.45
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.